Daptomycin suppresses tumor migration and angiogenesis via binding to ribosomal protein S19 in humans.

We have previously reported that daptomycin (DAP), a last resort antibiotic, binds to ribosomal protein S19 (RPS19) in humans and exhibits selective anti-cancer activity against MCF7 breast cancer cells. Here, we investigated the role of RPS19 in the anti-cancer effects of DAP and have found that DAP does not induce autophagy, apoptosis or cell viability but does reduce cell proliferation. Our results suggest that an extraribosomal function of RPS19 involves the regulation of vascular endothelial growth factor (VEGF) but not EGF, PDGF or FGF. Engagement of RPS19 by DAP was shown by CETSA and ITDRFCETSA assays, and knocking down of RPS19 with siRNA increased the potency of DAP in MCF7 cells. In addition, DAP suppressed the secretion of VEGF in cancer cells and thereby inhibited cell migration. Collectively, these data provide an outline of the underlying mechanism of how DAP exhibits anti-cancer activity and suggests that RPS19 could be a promising target for the development of new anticancer drugs. © 2021. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.

Citation

Sung Min Cho, Hwa Jung Lee, Peter Karuso, Ho Jeong Kwon. Daptomycin suppresses tumor migration and angiogenesis via binding to ribosomal protein S19 in humans. The Journal of antibiotics. 2021 Oct;74(10):726-733

Mesh Tags

Substances

PMID: 34253886

search → result